The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. Phase1b/2 clinical study to be conducted in the United States and several European countries. . Phase1b/2 clinical study to be conducted in the United States and several European countries. and Europe.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Neuroendocrine Tumors. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

Nedisertib is under clinical development by Merck and currently in Phase I for Head And Neck Cancer Squamous Cell Carcinoma. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. Merck is headquartered in Darmstadt, Hesse, Germany.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Drug Discovery World

FEBRUARY 28, 2024

CRISPR and brain cancer Meanwhile, elsewhere in the US, another exciting development – using CRISPR as a therapeutic approach – has possibilities for tackling brain cancer. The drug, MOv18 IgE (an anti-folate receptor alpha IgE antibody), was developed by researchers at King’s College London. expressing cancers.

Development 64

Development Research Drugs Antibody 64

Drug Discovery World

FEBRUARY 12, 2024

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” Developability prediction is often used in antibody development to reduce wet lab experiments and accelerate the drug discovery process.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Drug Discovery World

MAY 25, 2023

Several new products for the life sciences sector have been launched over the last month, from miniature semiconductor chip (MSC) technology to a new inhalation testing service. It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.

Production 52

Production Reagent DNA Drugs 52

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

NOVEMBER 1, 2020

Clinical Data Expected by End of Year. Tiziana Life Sciences plc. (“Tiziana” or the “Company”). C linical study will start dosing patients on November 3 rd , 202 0 with clinical data expected to be available before the end of 2020. About Tiziana Life Sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

pharmaphorum

MARCH 15, 2022

Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Sanofi has partnered with drug delivery specialist Enable Injections to develop the subcutaneous formulation.

Trials 82

Trials Sales Drug Delivery Antibody 82

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

pharmaphorum

APRIL 7, 2021

billion DKK ($672 million) from AbbVie after the companies struck an R&D deal to research epcoritamab, a bispecific antibody targeting CD3 and CD20 that the biotech developed in-house. Genmab has four technology platforms to draw from, with the most established being bispecific antibodies which target two receptors at once.

Antibody 65

Antibody Life Science Development Regulation 65

XTalks

JUNE 20, 2023

Columvi is a bispecific antibody designed to bind to CD3 on the surface of T cells and CD20 on the surface of B cells in a novel 1:2 structural format where one region of the antibody binds to CD3 and two to CD20. As part of the accelerated approval, Roche will have to conduct confirmatory trials for Columvi.

Antibody 98

Antibody Trials Drugs FDA Approval 98

Drug Discovery World

DECEMBER 13, 2023

This article is sponsored by Fortis Life Sciences. In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

XTalks

JULY 17, 2023

In a significant development, Astellas Pharma announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) had accepted their applications for Priority Review and Marketing Authorization respectively for zolbetuximab. Furthermore, atezolizumab is in Phase II clinical development by F.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Antibody 95

XTalks

NOVEMBER 4, 2022

The vaccine will instead be going up against long-acting antibodies being developed by AstraZeneca and Sanofi for administration in infants. In a Phase III clinical trial, the two pharma giants revealed one of the candidate antibodies, nirsevimab, led to 74.5

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

pharmaphorum

DECEMBER 15, 2020

On the back of phase 1b data the Copenhagen-based biotech said it had brought in new investors Sanofi Ventures, Adjuvant Capital and Industrifonden along with existing investors Novo Holdings, REPAIR Impact, Sunstone Life Science Ventures and LF Investment.

Bacteria 52

Bacteria Vaccination Vaccine Immune Response 52

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. Dr. Laport: Lunsumio (mosunetuzumab-axgb) is the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA.

FDA Approval 52

FDA Approval Drugs Antibody Medicine 52

XTalks

MARCH 1, 2021

Pfizer/BioNTech are executing the three-dose study to also determine the effectiveness of a third dose against evolving variants as part of their clinical development strategy. The third dose will be administered to the participants regardless of antibody titer levels.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

The Pharma Data

DECEMBER 8, 2020

December is bringing frost in the North and plenty of cold hard cash for these life sciences companies. . European venture capital firm Forbion rounded up $545 million for its fifth life sciences fund. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost.

RNA 52

RNA Antibody Life Science Protein 52

Roots Analysis

DECEMBER 18, 2023

This novel modality emerged when pharmaceutical developers used non-antibody-based entities as targeting ligand to develop targeted therapeutics. Similar to the structure of the antibody drug conjugates, these next generation drug conjugates use a non-antibody-based targeting ligand, a cytotoxic payload and a linker.

Drugs 40

Drugs FDA Approval Antibody Development 40

The Pharma Data

JANUARY 12, 2021

Food and Drug Administration (FDA) granted IO Biotech breakthrough therapy designation for a combination of the potential therapies IO102 and IO103 with anti-PD-1 monoclonal antibodies for patients with unresectable or metastatic melanoma. IO Biotech has a proven track record of progressing preclinical and clinical compounds.

In-Vivo 52

In-Vivo Antibody Vaccination Vaccine 52

XTalks

DECEMBER 10, 2021

Zavegepant is an antibody drug that prevents binding of the calcitonin gene-related peptide (CGRP) to the CGRP receptor. CGRP receptor antagonists are a new class of antibody drugs used for migraine treatment. The pain relief effects were sustained for up to 48 hours.

FDA Approval 98

FDA Approval Trials Drugs Sales 98

The Pharma Data

AUGUST 7, 2020

Most importantly, we are continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. We are committed to bringing these life-changing therapies to patients in need,” Lambert added.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Trials 52

pharmaphorum

MARCH 9, 2021

Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment that could be effective against emerging COVID-19 variants. Ablynx, which is now a subsidiary of Sanofi following a $4.8

Antibody 98

Antibody Life Science Scientist Vaccination 98

XTalks

JANUARY 17, 2024

“There were a range of therapies under discussion, from targeted therapies to advanced antibody-drug conjugates (ADCs) and cell and gene therapies,” he says.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

XTalks

MARCH 25, 2021

Pembrolizumab is a therapeutic monoclonal antibody that binds to and blocks the PD-1 receptor on the surface of lymphocytes. Treatment with a PD-1 antibody blocks the binding of PD-L1/2, preventing the repression of immune cell activation. Related: The 4 Biggest Cancer Biotech Acquisitions of 2021 So Far.

Trials 84

Trials Antibody Clinical Development Drugs 84

The Pharma Data

OCTOBER 26, 2020

He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program. AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group.

Development 52

Development Gene Therapy Engineer Life Science 52

XTalks

AUGUST 15, 2023

The treatment is the second win in oncology this month for Johnson & Johnson, which received approval for its bispecific antibody Talvey (talquetamab-tgvs) last week for the treatment of refractory or relapsed multiple myeloma. Akeega received its first global authorization from the European Commission (EC) in April this year.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

XTalks

OCTOBER 22, 2020

In this sense, pharmaceutical companies have developed different strategies to produce a wide variety of advanced therapy medicinal products (ATMP) and biological products, such as monoclonal antibodies, recombinant proteins, gene therapy viral vectors, CAR-T cells and oncolytic viruses, in order to deliver new medical needs in our society.

Manufacturing 98

Manufacturing Development Production Gene Therapy 98

pharmaphorum

MARCH 7, 2022

The World Health Organization (WHO) announced the opening of a global biomanufacturing hub located in South Korea to provide training to low- and middle-income countries seeking to produce vaccines and other biologics, such as insulin and monoclonal antibodies. . ” About the author .

Vaccination 97

Vaccination Vaccine Manufacturing Production 97

Pharmaceutical Technology

DECEMBER 22, 2022

The main focus is the antibody-drug conjugate (ADC ), Enhertu (trastuzumab deruxtecan), which had already achieved regulatory approval as a second-line therapy for metastatic or recurrent HER2-positive breast cancer, as well as HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Insulin 130

Insulin Production Development Genetics 130

Drug Discovery World

OCTOBER 18, 2022

A major contributor to the popularity of this city and the surrounding area is the specialised infrastructure and talented personnel that have accumulated over recent years, particularly in the life sciences industry. In fact, no other life sciences ecosystem in the world is developing as rapidly as the Basel Region.

Life Science 52

Life Science Engineer Research Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

The year is starting off with a number of biopharma and life sciences initial public offerings (IPOs). Other products include CLNB-049, a bispecific antibody against FLT3 and CD3 and CLN-619, a monoclonal antibody that simulates NK and T-cell responses. With this kind of a start, 2021 may be scorching.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

DECEMBER 27, 2020

The company’s individualized neoantigen-based immunotherapy, GRANITE, and its “off the shelf” shared neoantigen-based immunotherapy, SLATE, are being evaluated in clinical studies. Investors: Alexandra Santos Wheelhouse Life Science Advisors (510) 871-6161 asantos@wheelhouselsa.com. .

Sales 52

Sales Development Manufacturing Life Science 52

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”. “We

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. The antibodies produced as a result lodge in the kidneys, causing severe complications.

Marketing 74

Marketing Gene Silencing Gene Drugs 74